- CA$100.63m
- CA$75.66m
- CA$31.59m
- 88
- 48
- 87
- 87
Annual balance sheet for Biosyent, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 22 | 25.6 | 28.2 | 28.7 | 26.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.08 | 1.82 | 3.21 | 3.66 | 3.55 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 26.8 | 29.8 | 34.1 | 37.1 | 35.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.48 | 2.16 | 1.93 | 1.67 | 1.44 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 31 | 33.6 | 37.2 | 40.5 | 41.5 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.36 | 5.14 | 4.14 | 5.72 | 5.53 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Liabilities | 5.17 | 6.78 | 5.61 | 7.12 | 6.77 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 25.8 | 26.8 | 31.6 | 33.4 | 34.8 |
Total Liabilities & Shareholders' Equity | 31 | 33.6 | 37.2 | 40.5 | 41.5 |
Total Common Shares Outstanding |